Iovance Biotherapeutics CEO On TIL Immunotherapy For Solid Tumors

 
• By Sten Stovall
  
Laboratory
Iovance Is Developing Transformative Tumor-Infiltrating Lymphocyte (TIL) Therapies • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business